Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Mengwei Zhang (Shanghai Jiao Tong University, Renji Hospital), Jinkai Liu (Shanghai Jiao Tong University, Renji Hospital), Qiang Xia (Shanghai Jiao Tong University, Renji Hospital)
Résumé : Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients' response to immunotherapy. Several characteristics of the gut microbiome, such as community structures, taxonomic compositions, and molecular functions, have been identified as crucial biomarkers for predicting immunotherapy response and immune-related adverse events (irAEs). Unlike other -omics, the gut microbiome can serve as not only biomarkers but also potential targets for enhancing the efficacy of immunotherapy. Approaches for modulating the gut microbiome include probiotics/prebiotics supplementation, dietary interventions, fecal microbiota transplantation (FMT), and antibiotic administration. This review primarily focuses on elucidating the potential role of the gut microbiome in predicting the response to cancer immunotherapy and improving its efficacy. Notably, we explore reasons behind inconsistent findings observed in different studies, and highlight the underlying benefits of antibiotics in liver cancer immunotherapy.